论文部分内容阅读
目的:观察甘精胰岛素与亚莫利(格列美脲)对2型糖尿病患者联合治疗的临床效果,以及血糖的控制情况和低血糖的发生风险。方法:对178例2型糖尿病患者临床资料进行回顾性分析,按照治疗方法将其分为NPH(鱼精蛋白中效锌人胰岛素)组58例(A组),余下甘精胰岛素的治疗组50例(B组)以及甘精胰岛素与亚莫利联合治疗组70例(C组)。按照FBG(空腹血糖)的水平来调整患者胰岛素的用量,其治疗目标值为,FBG在7.0mmol/L以下,共治疗12周。对患者治疗后的血糖水平与血糖达标的时间以及低血糖的发生情况和BMI(体质指数)等指标进行观察。结果:3组患者经治疗后,其空腹血糖与餐后2h的血糖均显著低于治疗前的各组水平(P<0.05);C组患者低血糖的发生率显著低于AB两组(P<0.05);C组患者治疗前后的BMI不具有明显差异(P>0.05)。结论:对2型糖尿病患者应用甘精胰岛素与亚莫利联合治疗,不仅能够较好控制患者血糖,并且低血糖的发生率也较低,对患者体重影响也较小,具有方便安全等特点,为2型糖尿病患者理想的治疗方案。
Objective: To observe the clinical effects of insulin glargine and yamoxan (glimepiride) in combination therapy on type 2 diabetes mellitus and the control of blood glucose and the risk of hypoglycemia. Methods: The clinical data of 178 type 2 diabetic patients were retrospectively analyzed. According to the treatment, they were divided into NPH group (A group), NPH group (A group), and the remaining insulin glargine group Cases (group B) and insulin glargine and Yamogli combined treatment group of 70 patients (group C). In accordance with the level of FBG (fasting blood glucose) to adjust the amount of insulin in patients with the target value for the treatment, FBG at 7.0mmol / L or less for a total of 12 weeks. After treatment of patients with blood glucose levels and blood glucose compliance time and the incidence of hypoglycemia and BMI (body mass index) and other indicators were observed. Results: After treatment, fasting blood glucose and postprandial blood glucose were significantly lower in all three groups (P <0.05). The incidence of hypoglycemia in group C was significantly lower than that in groups AB <0.05). There was no significant difference in BMI between before and after treatment in group C (P> 0.05). Conclusion: The combination of insulin glargine and Yamogil in patients with type 2 diabetes mellitus can not only control the blood sugar of patients better, but also have a lower incidence of hypoglycemia and less influence on the body weight of patients with type 2 diabetes, which is convenient and safe. Ideal for type 2 diabetes patients.